Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares ...

Learn more about Viridian Elementary here - See an overview of the school, get student population data, enrollment information, test scores and more.

Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the first ...

At Viridian, we filled every available inch of our assigned counter space with plates and bowls piled high with food. The Oakland bar is best known for its cocktails. (Thien Pham) The Midnight Diners ...

Viridian Therapeutics has a couple of milestones upcoming in 2025 and more pivotal once scheduled in 2026. Click here to find out why VRDN stock is a Buy.

Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the biopharmaceutical company. Read more here.

Shares of Viridian Therapeutics Inc. VRDN fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease therapy ...

Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise ...

I got to test Viridian Weapon Technologies’ RFX45 Closed Emitter Green Dot Reflex Sight, which I saw for the first time during SHOT 2023. Unlike conventional LED optics, the RFX45 uses a green ...

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in ...

Viridian has reintroduced its entire C Series of pistol-mounted green laser sights and lights, and—as the only SKU incorporating each of these elements—the C5L represents the lineup’s most ...

Viridian Therapeutics Inc VRDN released preliminary data from its ongoing Phase 1/2 trial of VRDN-001 for chronic thyroid eye disease (TED). Patients in the 10 mg/kg (n=6) and 3 mg/kg (n=6 ...